The Patent Finder
US

Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy

US 11,639,927 In force
OverviewFamilyAssignmentsSources & methods

Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.

Term ends Jun 25, 2030 · High confidence

Filed Sep 29, 2020 as application 17/036,110 · Granted May 2, 2023
Base term plus 166 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
2010 2030
Clock starts
Jun 25, 2010
Term ends
Jun 25, 2030
Granted
May 2, 2023
base term fee events Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
166
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,139,399, US 10,823,727, US 9,377,454.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
13
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 166 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 1 maintenance fees is paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 25, 2010, when applications PCT/US2010/004008 and PCT/US2010/040082, the earliest non-provisional applications in its chain, were filed (this one was filed Sep 29, 2020)Jun 25, 2030High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+166 days, USPTO patent term adjustment recordDec 8, 2030High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 10,139,399, US 10,823,727, US 9,377,454)capped to Jun 25, 2030High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 1 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderJun 25, 2030High confidence

Partial family

Application PCT/US2010/004008PCT application
no patent term
no patent term
Application PCT/US2010/040082PCT application
no patent term
no patent term
US 9,377,454In force
Jun 2030
Jun 2030
Application 15/165,318Abandoned
not computed
not computed
US 10,139,399In force
Jun 2030
Jun 2030
US 10,823,727In force
Jun 2030
Jun 2030
US 11,639,927this patent
Jun 2030
Jun 2030
US 11,598,767In force
Jun 2030
Jun 2030
8 of 13 applications in this family shown, earliest filings first. Partial: 1 of the 13 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Mar 15, 2021
Reel 55659, frame 430
Horizon Orphan LLC; Horizon Therapeutics USA, Inc.; Viela Bio, Inc.Citibank, N.a.Security Agreement
May 27, 2021
Reel 56369, frame 172
Rosario-jansen, Theresa; Wright, David ErickSavient Pharmaceuticals, Inc.Assignment of Assignor's Interest
May 27, 2021
Reel 56408, frame 201
Savient Pharmaceuticals, Inc.Crealta Pharmaceuticals LLCAssignment of Assignor's Interest
May 27, 2021
Reel 56408, frame 238
Crealta Pharmaceuticals LLCHorizon Pharma USA Rheumatology LLCChange of Name
May 27, 2021
Reel 56408, frame 241
Horizon Pharma USA Rheumatology LLCHorizon Pharma Rheumatology LLCChange of Name
Dec 13, 2022
Reel 62117, frame 155
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Assignment of Assignor's Interest
Oct 6, 2023
Reel 65154, frame 64
Citibank, N.a.Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC); Horizon Therapeutics USA, Inc.; Viela Bio, Inc.Release of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC)Release of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.Horizon Therapeutics USA, Inc.Release of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.Viela Bio, Inc.Release of Security Interest
Nov 6, 2026
Reel 76662, frame 840
Horizon Therapeutics USA, Inc.Horizon Therapeutics Ireland DacAssignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited